292068-37-2

Basic information

• Product Name: Benzenemethanamine, 4-ethyl-a-methyl-, (aR)-
• Synonyms: Benzenemethanamine, 4-ethyl-a-methyl-, (aR)-;Benzenemethanamine, 4-ethyl-α-methyl-, (αR)-;4-ethyl-a-Methyl-;(R)-1-(4-ethylphenyl)ethan-1-amine
• CAS NO: 292068-37-2
• Molecular Formula: C10H15N
• Molecular Weight: 149.236
• Product Categories: API intermediates
• Mol File: 292068-37-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 229.7°C at 760 mmHg
• Flash Point: 97.5°C
• Appearance: /
• Density: 0.935g/cm³
• Vapor Pressure: 0.0687mmHg at 25°C
• Refractive Index: 1.525
• CAS DataBase Reference: Benzenemethanamine, 4-ethyl-a-methyl-, (aR)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, 4-ethyl-a-methyl-, (aR)-(292068-37-2)
• EPA Substance Registry System: Benzenemethanamine, 4-ethyl-a-methyl-, (aR)-(292068-37-2)

Safety Data

• Hazardous Substances Data: 292068-37-2(Hazardous Substances Data)

Usage

General Description

Benzenemethanamine, 4-ethyl-a-methyl-, (aR)-, also known as ephedrine, is a chemical compound with stimulant and bronchodilator properties. It is commonly used as a decongestant for the relief of asthma, bronchitis, and other respiratory conditions. Ephedrine works by stimulating the alpha and beta-adrenergic receptors in the sympathetic nervous system, leading to increased heart rate and blood pressure, dilation of the bronchial passages, and constriction of blood vessels. It is also used as a precursor in the illicit production of methamphetamine and has been banned in many countries due to its potential for abuse and adverse effects on the cardiovascular system.

InChI:InChI=1/C10H15N/c1-3-9-4-6-10(7-5-9)8(2)11/h4-8H,3,11H2,1-2H3/t8-/m1/s1

Upstream product

• 937-30-4 4-ethylacetophenone 
• 147116-33-4 1-(4-ethylphenyl)ethylamine 

Relevant articles and documents

Catalytic asymmetric oxidative carbonylation-induced kinetic resolution of sterically hindered benzylamines to chiral isoindolinones

A highly enantioselective kinetic resolution of sterically hindered benzylamines has been achieved for the first time through transition-metal-catalyzed oxidative carbonylation, in which the new KR strategy offered a new approach to afford chiral isoindolinones (er up to 97?:?3) and the origin of chemoselectivity and stereoselectivity was confirmed by density functional theory (DFT) calculations.

Method for synthesizing chiral amine compound

The present invention provides a method for synthesizing a chiral amine compound. The method comprises the following steps: (1) reacting a compound of formula I with t-butylsulfonamide in the presenceof a catalyst to obtain a compound having a structure represented by formula II; 2) reacting the compound of the formula II in a hydrogen atmosphere in the presence of an iridium catalyst and a ligand to obtain a compound of formula III; and (3) carrying out a t-butylsulfonyl group removal reaction on the compound of the formula III to obtain the chiral amine compound. The method constructs the structure of sulfonamide by a keto carbonylgroup, and synthesizes the chiral amine compound with the aralkylamine structure by an asymmetric catalytic hydrogenation reaction of the sulfonamide structure, the ee value is generally 80% or above, the highest ee value is 99% or above, the yield of each step reaction can reach 90% or above, and the total yield is high.

Resolution of 1-arylalkylamines with 3-O-hydrogen phthalate glucofuranose derivatives: Role of steric bulk in a family of resolving agents

The development of three new acidic resolving agents which are hydrogen phthalates of 1,2:5,6-di-O-isopropylidene-α-d-glucofuranose 1, 1,2:5,6-di-O-cyclohexylidene-α-d-glucofuranose 2 and 1,2-O- cyclohexylidene-5,6-O-diphenylmethylidene-α-d-glucofuranose 3 is shown for the resolution of 1-arylalkylamines 7a-k. The salts between 1, 2 and (RS)-1-arylalkylamines 7a-k selectively crystallize 1?(S) 7a-j and 2?(S) 7a-h salts, allowing us to recover the corresponding bases (S) 7a-j and (S) 7a-h, respectively, in good yield and enantiomeric excess (73-95% ee). Whereas, the salts between 3 and (RS)-1-arylalkylamines 7a-c,g-i,k selectively crystallize 3?(S)-7a-c,g-i salts to recover the corresponding bases (S)-7a-c,g-i in poor enantiomeric excess (4-35% ee). The difference between the resolving ability of 1 and 2 for 1-arylalkylamines 7a-h is very slight, but there is considerable difference compared to ortho-substituted 1-arylalkylamines 7i and 7j. The role of substituents on a family of resolving agents 1, 2 and 3 is also discussed to interpret their resolving ability.